Clinical Trials & Research

Friday, December 11, 2020 U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. immediately Pfizer and BioNTech previously announced an agreement with the U.S. Government to supply doses in 2020 & 2021 In collaboration with Operation Warp Speed, Pfizer and BioNTech, as well as other
Thursday, December 10, 2020 -  Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose Vaccine efficacy observed in the overall study
Dec 10 2020 The Differential Refractive Index (DRI) detector from Testa Analytical Solution e.K offers unmatched accuracy and reliability for determination of absolute concentration and total mass balance in Gel Permeation Chromatography / Size Exclusion Chromatography (GPC/SEC) applications The baseline signal stability of any liquid chromatography detector is very important, as it is a limiting
8 December 2020 — Results of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222, peer-reviewed and published in The Lancet today, demonstrated that the vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects against severe disease and hospitalisation. The interim analysis for efficacy was based on 11,636
CAMBRIDGE, Mass.–(BUSINESS WIRE) December 5, 2020 — Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from its Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine in two acute myeloid leukemia (AML) patient
NEW YORK & MAINZ, Germany–(BUSINESS WIRE) December 02, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use
NEW YORK–(BUSINESS WIRE) November 23, 2020 — Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors. BASIS is a
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 30, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.
The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). Calculation was based on the analysis of data on volunteers (n = 18,794) who received both the first and second doses of the Sputnik
5 Ways to Detox Your Body Do you really feel exhausted, slow-moving, or simply simple undesirable? If so, the solution to your problems may stock a body detoxification, also commonly known as a body clean. With a clean, you permit your body to expel the possibly unsafe contaminants it has actually accumulated throughout the years.
November 25, 2020 — Under FDA law, approval of a new drug requires substantial evidence of effectiveness and a demonstration of safety for the drug’s intended use(s).  The approval of remdesivir (Veklury) for the treatment of patients hospitalized with COVID-19 met this legal and scientific standard. BackgroundRandomized, controlled trials are the gold standard for evaluating
23 November 2020  Two different dosing regimens demonstrated efficacy with one showing a better profile No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222  Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary
Nov 24 2020 Allerød, Denmark –Pharmaceutical companies worldwide are diligently working overtime to produce an accepted COVID-19 vaccine. While this work continues, other companies are already planning how to distribute a potential vaccine.  Perhaps the most significant challenge exists in temperature control, as some COVID-19 vaccine candidates will require ultra-low temperature (ULT), typically ranging from
KENILWORTH, N.J.–(BUSINESS WIRE) November 16, 2020 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP)1
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 16, 2020– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met
Nov 20 2020 Life science, research and industrial laboratories undertaking temperature control applications can now minimize the environmental footprint of their operations with a new range of digitally-controlled bath circulators designed to enable significant water and energy savings, while using low global warming potential (GWP) hydrocarbon refrigerants. Offering superior performance, ease of use, and flexible,
Wednesday, November 18, 2020 Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults
Reviewed by Emily Henderson, B.Sc.Nov 18 2020 Using a remotely-delivered, algorithm-driven program for disease management, patients experienced significant improvement in cholesterol and blood pressure levels, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2020. The virtual meeting is Friday, November 13-Tuesday, November 17, 2020, and is a premier global exchange